Key facts
- Notable investors include Hefei Industry Investment Group, GF Xinde Investment Management, Dalton Venture, ShareLink Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Kreinform Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Kreinform Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kreinform Technology
Developer of ophthalmic and cell therapy drugs designed to advance treatment options for eye diseases and related medical conditions. The company offers innovative drug research capabilities, cell technology development and drug testing instrument applications, enabling healthcare and pharmaceutical sectors to improve access to next-generation therapeutic development and clinical advancement pathways.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Kreinform Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kreinform Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kreinform Technology in its N-PORT filings yet. We sweep new filings monthly.